References
- Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet338, 732–736 (1991).
- Rietschel ET, Kirikae T, Schade F et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J.8, 217–225 (1994).
- Schletter J, Heine H, Ulmer AJ, Rietschel ET. Molecular mechanisms of endotoxin activity. Arch. Microbiol.164, 383–389 (1995).
- Zahringer U, Lindner B, Rietschel ET. Molecular structure of lipid A, the endotoxic center of bacterial lipopolysaccharides. Adv. Carbohydr. Chem. Biochem.50, 211–276 (1994).
- Galanos C, Luderitz O, Rietschel ET et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem.148, 1–5 (1985).
- Hoffmann JA, Kafatos FC, Janeway CA Jr, Ezekowitz RAB. Phylogenetic perspectives in innate immunity. Science284, 1313–1318 (1999).
- Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem.274, 10689–10692 (1999).
- Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science282, 2085–2088 (1998).
- Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol.162, 3749–3752 (1999).
- Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol.13, 437–457 (1995).
- Shimazu R, Akashi S, Ogata H et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med.189, 1777–1782 (1999).
- Akashi S, Nagai Y, Ogata H et al. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Internat. Immun.13, 1595–1599 (2001).
- Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science316, 1632-1634 (2007).
- Pedron T, Girard R, Eustache J et al. New synthetic analogs of lipid A as lipopolysaccharide agonists or antagonists of B lymphocyte activation. Inter. Immunol.4, 533–540 (1992).
- Zahringer U, Lindner B, Rietschel ET. Chemical structure of lipid A: recent advances in structural analysis of biologically active molecules. In: Endotoxin in Health and Disease. Brade H, Opal SM, Vogel SN, Morrison DC (Eds). Marcel Dekker Inc., NY, USA 93–114 (1999).
- Kusumoto S, Fukase K Oikawa M. The chemical synthesis of lipid A. In: Endotoxin in Health and Disease. Brade H, Opal SM, Vogel SN, Morrison DC (Eds). Marcel Dekker Inc., NY, USA 243–256 (1999).
- Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ and Ribi.529. Expert Rev. Vaccines2, 219–229 (2003).
- Johnson DA, Keegan DS, Sowell CG et al. 3-O-desacyl monophosphoryl lipid A derivatives. J. Med. Chem.42, 4640–4649 (1999).
- Cluff CW, Baldridge JR, Stöver AG et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun.73, 3044–3052 (2005).
- Schromm AB, Brandenburg K, Loppnow H et al. The charge of endotoxin molecules influences their conformation and interleukin-6 inducing capacity. J. Immunol.161, 5464–5471 (1998).
- Schromm AB, Brandenburg K, Loppnow H et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur. J. Biochem.267, 2008–2013 (2000).
- Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharide binding protein. Science249, 1429–1431 (1990).
- Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science249, 1431–1433 (1990).
- Gutsmann T, Haberer N, Carroll SF, Seydel U, Wiese A. Interaction between lipopolysaccharide (LPS), LPS-binding protein (LBP), and planar membranes. Biol. Chem.382, 425–434 (2001).
- Blunck R, Scheel O, Müller M, Brandenburg K, Seitzer U, Seydel U. New insights into endotoxin-induced activation of macrophages: Involvement of a K+ channel in transmembrane signalling. J. Immunol.166, 1009–1015 (2001).
- Krisovitch SM, Regen SL. Nearest-neighbor recognition in phosopholipid membranes: a molecular-level approach to the study of membrane suprastructure. J. Am. Chem. Soc.114, 9828–9835 (1992).
- Davidson SMK, Regen SL. Nearest-neighbor recognition in phospholipid membranes. Chem. Rev.97, 1269–1279 (1997).
- Brandenburg K, Garidel P, Howe J et al. What can calorimetry tell us about changes of three-dimensional aggregate structures of phospholipid and glycolipids? Thermochim. Acta445, 133–145 (2006).
- Seydel U, Hawkins L, Schromm AB et al. The generalized endotoxic principle. Eur. J. Immunol.33, 1586–1592 (2003).
- Brandenburg K, Hawkins L, Garidel P et al. Structural polymorphism and endotoxic activity of synthetic phospholipid-like amphiphiles. Biochem.43, 4039–4046 (2004).
- Brandenburg K, Mayer H, Koch MHJ, Weckesser J, Rietschel ET, Seydel U. Influence of the supramolecular structure of free lipid A on its biological activity. Eur. J. Biochem.218, 555–563 (1993).
- Hawkins LD, Ishizaka ST, McGuinness P et al. A novel class of endotoxin receptor agonists with simplified structure, Toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J. Pharmacol. Exp. Ther.300(2), 655–661 (2002).
- Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol.5(7), 730–737 (2004).
- Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem.278(11), 8869–8872 (2003).
- Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature410(6832), 1099–1103 (2001).
- Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol.1(5), 398–401 (2001).
- Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J. Immunol.164(2), 558–561 (2000).
- Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem.276(13), 10229–10233 (2001).
- Zhang FX, Kirschning CJ, Mancinelli R et al. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem.274(12), 7611–7614 (1999).
- Fitzgerald KA, Rowe DC, Barnes BJ et al. LPS-TLR4 signaling to IRF-3/7 and NFκB involves the Toll adapters TRAM and TRIF. J. Exp. Med.198(7), 1043–1055 (2003).
- Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science316, 1628–1632 (2007).
- Ganley-Leal LM, Liu X, Wetzler LM. Toll-like receptor 2-mediated human B cell differentiation. Clin. Immunol.120(3), 272–284 (2006).
- Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol.24(6), 693–701 (2004).
- Vandepapeliere P, Rehermann B, Koutsoukos M et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine23(20), 2591–601 (2005).
- Dai J, Megjugorac NJ, Amrute SB, Fitzgerald-Bocarsly P. Regulation of IFN regulatory factor-7 and IFN-α production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. J. Immunol.173(3), 1535–1548 (2004).
- Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med.197(4), 403–411 (2003).
- Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science299(5609), 1033–1036 (2003).
- Seya T, Akazawa T, Tsumita T, Matsumoto M. Role of toll-like receptors in adjuvant-augmented immune therapies. Evid. Based Complement. Alternat. Med.3(1), 31–38 (2006).
- Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CRH. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J. Biol. Chem.266, 19490–19498 (1991).
- Rose JR, Christ WJ, Bristol JR, Kawata T, Rossignol DP. Agonistic and antagonistic activities of bacterially derived rhodobacter sphaeroides lipid A: comparison with activities of synthetic material of the proposed structure of analogs. Infect. Immun.63, 833–839 (1995).
- Peng S. Signaling in B cells via Toll-like receptors. Curr. Opin. Immunol.17(3), 230–236 (2005).
- Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med.194(6), 863–869 (2001).
- Krug A, Towarowski Britsch S et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol.31, 3026–3037 (2001).
- Steinman L. A brief history of Th17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat. Med.13(2), 139–145 (2007).
- Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev.212, 8–27 (2006).
- Gavin AL, Hoebe K, Duong B et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science314(5807), 1936–1938 (2006).
- Manetti R, Parronchi P, Giudizi MG et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med.177(4), 1199–1204 (1993).
- Przetak M, Chow J, Cheng H, Rose J, Hawkins LD, Ishizaka ST. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine21(9–10), 961–970 (2003).
- Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activated caspase-1 and induce IL-1 and IL-18 release. J. Immunol.178, 5471–5276 (2007).
- Franz S, Kobzik L, Kim Y-D et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest.104, 271–280 (1999).
- de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc. Res.60, 58–67 (2003).
- Sukkar MB, Kie S, Khorasani NM et al. Toll-like receptor 2, 3, 4 expression and function in human airway smooth muscle. J. Allergy Clin. Immunol.118, 641–648 (2006).
- Morris GE, Whyte MKB, Martin GF, Jose PJ, Dower SK, Sabroe I. Agonists of Toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes. Am. J. Respir. Crit. Care Med.171, 814–822 (2005).
- Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by Toll-like receptor agonists. Am. J. Respir. Cell Mol. Biol.31, 358–364 (2004).
- Armstrong L, Medford ARL, Uppington KM et al. Expression of Toll-like receptor-2 and -4 on alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol.31, 241–245 (2004).
- Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res.57(8), 1419–1424 (1997).
Patent
- Fang FG, Foy JE, Hawkins L et al. Process for preparation of ureido phosphate ester TLR4 receptor agonist useful as immunological adjuvant for administration with bacterial and viral vaccines. PCT Int. Appl. WO2007005583 (2007).